2021-11-16-世界卫生组织-Cervical_cancer_Kiribati_2021_country_profile_1页_64kb

Kiribati Cervical Cancer Summary

Morbidity and Mortality

• Cervical cancer incidence data (crude, age-standardized, cumulative risk) are mostly not available (ND) for 2020 or 2020-based.
• Cervical cancer deaths in 2019 were 610 out of a female population of 60,000, giving a crude death rate of approximately 1.02 per 100,000 women.
• Mortality-to-incidence ratio is not available for 2020.

Primary Prevention

• HPV vaccination coverage among girls aged 9-14 years is 27% for 2020.
• There is an HPV vaccination program, but HPV is not included in the national vaccination schedule.
• Year of introduction, scale, and target cohort details are not specified.
• Related risk factors data (tobacco use, condom use, HIV incidence) are not available (ND) for 2020.

Secondary Prevention

• A national screening program for cervical cancer exists, with cervical cancer cited in indicators for WHO elimination strategy.
• Primary screening test used is cytology.
• Target age range for screening is 25-65 years, but only 18% of women aged 30-49 years have ever been screened in the last 5 years.
• Referral systems and early detection guidelines at primary health care are not defined or available.

Treatment and Supportive Care

• National guidelines on cervical cancer management exist.
• Cancer diagnosis and treatment services are limited; specific details on radiotherapy, brachytherapy, and staff availability are not available (ND or minimal data).
• Cancer centers and specialists (e.g., radiation oncologists, pathologists) are not specified or unavailable.

WHO Elimination Strategy Targets for 2030

• Progress on targets: 90% HPV vaccination by age 15, 70% high-performance screening by ages 35 and 45, and 90% treatment for cervical disease are not fully met or data are ND; but indicated coverage exists.

Overall, cervical cancer control in Kiribati faces significant data gaps and limited preventive and treatment services. Primary prevention shows some activity (e.g., HPV vaccination), but secondary prevention and treatment efforts are restricted.